TDMS Study 61427-08 Pathology Tables
NTP Experiment-Test: 61427-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC VANADIUM PENTOXIDE Date: 11/19/01
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:27:41
FINAL#2/MICE
Facility: Battelle Northwest
Chemical CAS #: 1314-62-1
Lock Date: 11/02/99
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 61427-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC VANADIUM PENTOXIDE Date: 11/19/01
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:27:41
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 1.0 2.0 4.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Moribund Sacrifice 8 10 14 16
Natural Death 4 5 4 2
Accidently Killed 3 2
Survivors
Terminal Sacrifice 38 32 29 32
Moribund Sacrifice 1
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Cecum (47) (44) (48) (49)
Leiomyosarcoma 1 (2%)
Intestine Small, Duodenum (47) (43) (46) (49)
Polyp Adenomatous 1 (2%)
Intestine Small, Jejunum (47) (43) (45) (50)
Histiocytic Sarcoma 1 (2%)
Intestine Small, Ileum (47) (43) (46) (50)
Histiocytic Sarcoma 1 (2%)
Liver (50) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Hepatocellular Carcinoma 6 (12%) 3 (6%) 4 (8%) 6 (12%)
Hepatocellular Carcinoma, Multiple 1 (2%)
Hepatocellular Adenoma 5 (10%) 5 (10%) 9 (18%) 1 (2%)
Hepatocellular Adenoma, Multiple 1 (2%) 2 (4%) 1 (2%)
Histiocytic Sarcoma 2 (4%) 1 (2%) 1 (2%) 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Mesentery (14) (9) (5) (4)
Fat, Hemangioma 1 (20%)
Fat, Schwannoma Malignant, Metastatic, Uterus 1 (25%)
Oral Mucosa (1)
Squamous Cell Carcinoma 1 (100%)
Pancreas (50) (50) (49) (50)
Histiocytic Sarcoma 2 (4%) 1 (2%)
Salivary Glands (50) (50) (50) (50)
Stomach, Forestomach (50) (50) (50) (50)
Page 2
NTP Experiment-Test: 61427-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC VANADIUM PENTOXIDE Date: 11/19/01
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:27:41
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 1.0 2.0 4.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Squamous Cell Carcinoma 1 (2%)
Squamous Cell Papilloma 2 (4%)
Stomach, Glandular (49) (47) (48) (50)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Pericardium, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (49) (49)
Adrenal Medulla (49) (50) (48) (49)
Pheochromocytoma Benign 2 (4%) 3 (6%)
Pituitary Gland (49) (50) (50) (47)
Histiocytic Sarcoma 1 (2%)
Pars Distalis, Adenoma 8 (16%) 6 (12%) 7 (14%) 3 (6%)
Thyroid Gland (50) (50) (48) (50)
Bilateral, Follicular Cell, Adenoma 1 (2%)
C-Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Peritoneum (1)
Schwannoma Malignant, Metastatic, Uterus 1 (100%)
Tissue NOS (1)
Abdominal, Histiocytic Sarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (48) (50) (49) (47)
Cystadenoma 1 (2%) 1 (2%) 2 (4%)
Granulosa Cell Tumor Malignant 1 (2%)
Histiocytic Sarcoma 2 (4%) 1 (2%) 1 (2%)
Uterus (50) (49) (49) (50)
Page 3
NTP Experiment-Test: 61427-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC VANADIUM PENTOXIDE Date: 11/19/01
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:27:41
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 1.0 2.0 4.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 2 (4%) 1 (2%) 1 (2%)
Polyp Stromal 1 (2%) 2 (4%) 3 (6%) 1 (2%)
Polyp Stromal, Multiple 1 (2%)
Sarcoma Stromal 1 (2%)
Schwannoma Malignant, Metastatic, Uterus 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (50)
Hemangiosarcoma 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Lymph Node (3) (1) (5) (1)
Iliac, Histiocytic Sarcoma 1 (20%)
Pancreatic, Histiocytic Sarcoma 1 (20%)
Renal, Histiocytic Sarcoma 1 (20%)
Lymph Node, Bronchial (39) (40) (45) (41)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (3%) 1 (2%)
Histiocytic Sarcoma 1 (3%) 1 (2%)
Lymph Node, Mandibular (41) (40) (40) (46)
Histiocytic Sarcoma 1 (2%) 1 (3%) 1 (3%) 1 (2%)
Lymph Node, Mesenteric (46) (47) (48) (50)
Fibrous Histiocytoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%) 1 (2%)
Schwannoma Malignant, Metastatic, Uterus 1 (2%)
Lymph Node, Mediastinal (43) (37) (42) (42)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (3%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (3%) 1 (2%) 1 (2%)
Spleen (50) (48) (49) (50)
Hemangiosarcoma 2 (4%) 1 (2%) 2 (4%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Thymus (44) (45) (44) (41)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 61427-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC VANADIUM PENTOXIDE Date: 11/19/01
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:27:41
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 1.0 2.0 4.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50) (50) (50) (50)
Carcinoma 1 (2%)
Skin (50) (50) (50) (50)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%) 1 (2%)
Subcutaneous Tissue, Histiocytic Sarcoma 1 (2%)
Subcutaneous Tissue, Sarcoma 2 (4%) 2 (4%) 2 (4%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (1)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Larynx (50) (50) (49) (50)
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 1 (2%) 14 (28%) 18 (36%) 13 (26%)
Alveolar/Bronchiolar Adenoma, Multiple 3 (6%) 5 (10%) 6 (12%)
Alveolar/Bronchiolar Carcinoma 14 (28%) 13 (26%) 17 (34%)
Alveolar/Bronchiolar Carcinoma, Multiple 9 (18%) 5 (10%) 5 (10%)
Granular Cell Tumor Malignant, Metastatic,
Ovary 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 2 (4%) 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%) 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Mediastinum, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 2 (4%) 2 (4%)
Nose (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 5
NTP Experiment-Test: 61427-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC VANADIUM PENTOXIDE Date: 11/19/01
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:27:41
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 1.0 2.0 4.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (3) (1) (1)
Adenoma 1 (100%) 1 (100%)
Bilateral, Adenoma 2 (67%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (49) (50)
Carcinoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Urinary Bladder (48) (45) (48) (49)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 3 (6%) 1 (2%) 1 (2%) 1 (2%)
Lymphoma Malignant 7 (14%) 4 (8%) 12 (24%) 5 (10%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 61427-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC VANADIUM PENTOXIDE Date: 11/19/01
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:27:41
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 1.0 2.0 4.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 32 37 44 40
Total Primary Neoplasms 49 67 88 73
Total Animals with Benign Neoplasms 19 23 35 27
Total Benign Neoplasms 25 34 46 30
Total Animals with Malignant Neoplasms 17 29 32 32
Total Malignant Neoplasms 24 33 42 43
Total Animals with Metastatic Neoplasms 2 2 3 5
Total Metastatic Neoplasm 2 8 3 12
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 7
NTP Experiment-Test: 61427-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC VANADIUM PENTOXIDE Date: 11/19/01
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:27:41
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 1.0 2.0 4.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Natural Death 4 6 1 3
Moribund Sacrifice 7 11 13 20
Survivors
Terminal Sacrifice 39 33 36 27
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Small, Duodenum (48) (47) (49) (45)
Carcinoma 1 (2%)
Intestine Small, Ileum (46) (49) (50) (48)
Carcinoma 1 (2%)
Liver (50) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Hemangiosarcoma 1 (2%) 1 (2%)
Hepatocellular Carcinoma 10 (20%) 13 (26%) 11 (22%) 9 (18%)
Hepatocellular Carcinoma, Multiple 4 (8%) 5 (10%) 3 (6%) 3 (6%)
Hepatocellular Adenoma 10 (20%) 10 (20%) 8 (16%) 6 (12%)
Hepatocellular Adenoma, Multiple 5 (10%) 7 (14%) 2 (4%) 1 (2%)
Hepatocholangiocarcinoma 1 (2%)
Mesentery (9) (7) (8) (1)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 2 (29%)
Hemangioma 1 (14%)
Fat, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (13%)
Fat, Hepatocholangiocarcinoma, Metastatic,
Liver 1 (13%)
Pancreas (50) (50) (50) (50)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Stomach, Forestomach (50) (50) (50) (50)
Squamous Cell Papilloma 2 (4%) 1 (2%)
Stomach, Glandular (50) (49) (50) (50)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Tongue (1)
Squamous Cell Papilloma 1 (100%)
Page 8
NTP Experiment-Test: 61427-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC VANADIUM PENTOXIDE Date: 11/19/01
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:27:41
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 1.0 2.0 4.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 2 (4%) 1 (2%) 2 (4%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Pericardium, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (2%)
Pericardium, Hepatocellular Carcinoma,
Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (49) (50) (50)
Adenoma 1 (2%)
Adrenal Medulla (50) (49) (49) (50)
Pheochromocytoma Benign 1 (2%) 1 (2%)
Islets, Pancreatic (50) (50) (50) (50)
Adenoma 1 (2%)
Pituitary Gland (50) (48) (49) (49)
Pars Distalis, Adenoma 1 (2%)
Pars Distalis, Carcinoma 1 (2%)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (48) (50) (50) (50)
Carcinoma, Metastatic, Parathyroid Gland 1 (2%)
C-Cell, Carcinoma 1 (2%)
Follicular Cell, Adenoma 2 (4%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Prostate (50) (49) (49) (49)
Page 9
NTP Experiment-Test: 61427-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC VANADIUM PENTOXIDE Date: 11/19/01
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:27:41
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 1.0 2.0 4.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Seminal Vesicle (50) (50) (50) (50)
Adenoma 1 (2%)
Testes (50) (50) (50) (50)
Interstitial Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Lymph Node (1) (1)
Lumbar, Histiocytic Sarcoma 1 (100%)
Lymph Node, Bronchial (40) (38) (36) (40)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (3%) 1 (3%) 2 (5%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (3%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (3%)
Histiocytic Sarcoma 1 (3%)
Lymph Node, Mandibular (34) (43) (27) (35)
Histiocytic Sarcoma 1 (2%)
Lymph Node, Mesenteric (46) (47) (48) (44)
Carcinoma, Metastatic, Tissue NOS 1 (2%)
Hemangioma 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Lymph Node, Mediastinal (38) (36) (43) (37)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (3%) 2 (5%) 2 (5%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (3%)
Spleen (50) (50) (50) (50)
Hemangiosarcoma 3 (6%)
Histiocytic Sarcoma 1 (2%)
Thymus (35) (40) (36) (35)
Hemangiosarcoma 1 (3%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (50) (50) (50)
Hemangiosarcoma 1 (2%) 1 (2%)
Melanoma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
Page 10
NTP Experiment-Test: 61427-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC VANADIUM PENTOXIDE Date: 11/19/01
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:27:41
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 1.0 2.0 4.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Skeletal Muscle (3) (2) (3)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 3 (100%) 1 (50%) 3 (100%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (50%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (49) (50) (50)
Carcinoma, Metastatic, Pituitary Gland 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 12 (24%) 15 (30%) 15 (30%) 10 (20%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 1 (2%) 11 (22%) 5 (10%)
Alveolar/Bronchiolar Carcinoma 11 (22%) 19 (38%) 14 (28%) 22 (44%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%) 10 (20%) 16 (32%) 13 (26%)
Carcinoma, Metastatic, Harderian Gland 1 (2%) 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 7 (14%) 4 (8%) 4 (8%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Mediastinum, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 3 (6%) 2 (4%) 5 (10%)
Mediastinum, Hepatocellular Carcinoma,
Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (1) (1)
Neural Crest Tumor 1 (100%)
Harderian Gland (8) (5) (5) (2)
Adenoma 6 (75%) 4 (80%) 4 (80%) 1 (50%)
Carcinoma 1 (20%) 1 (50%)
Bilateral, Adenoma 2 (25%) 1 (20%)
____________________________________________________________________________________________________________________________________
Page 11
NTP Experiment-Test: 61427-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC VANADIUM PENTOXIDE Date: 11/19/01
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:27:41
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 1.0 2.0 4.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (50)
Adenoma 1 (2%) 1 (2%)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 3 (6%) 2 (4%) 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Urinary Bladder (50) (50) (50) (50)
Papilloma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%)
Lymphoma Malignant 2 (4%) 2 (4%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 12
NTP Experiment-Test: 61427-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC VANADIUM PENTOXIDE Date: 11/19/01
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:27:41
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 1.0 2.0 4.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 42 49 47 47
Total Primary Neoplasms 75 96 92 81
Total Animals with Benign Neoplasms 31 31 36 21
Total Benign Neoplasms 44 42 44 26
Total Animals with Malignant Neoplasms 27 40 38 41
Total Malignant Neoplasms 31 53 48 55
Total Animals with Metastatic Neoplasms 1 11 9 11
Total Metastatic Neoplasm 1 23 33 22
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1
Total Uncertain Neoplasms 1
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 13
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------